Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TONES 2: Solriamfetol in Narcolepsy
NCT02348593Phase 3Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- May 2015
- Primary completion
- Feb 2017
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial of solriamfetol in narcolepsy (4 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoints: Change in Maintenance of Wakefulness Test Sleep Latency at 12 weeks and Change in Epworth Sleepiness Scale at 12 weeks. Started May 2015; status: completed.
02
Drugs
solriamfetol
03
Conditions
narcolepsy
Beyond the preview
Go deeper on NCT02348593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02348593.